MedTrace Logo

DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial

NCT05305482 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3520

Last updated 2025-05-21

No results posted yet for this study

Summary

To test whether the polymer-free drug-coated stent (DCS) BioFreedom is noninferior to the biodegradable polymer drug-eluting stent (DES) Ultimaster in terms of 1-year patient-oriented composite endpoint (POCE, composite of all-cause mortality, any MI, or any revascularization) in a setting of 1-month dual-antiplatelet therapy (DAPT) strategy (1-month DAPT followed ticagrelor monotherapy) after acute coronary syndrome.

Conditions

  • Acute Coronary Syndrome

Interventions

DEVICE

Drug-coated stent

The polymer-free drug-coated stent (BioFreedom Ultra stent) will be implanted for the DCS group.

DEVICE

Drug-eluting stent

The Biodegradable polymer drug-eluting stent (Ultimaster stent) will be implanted for the DES group.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Chul-Min Ahn · Yonsei University Health System, Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-10
Primary Completion
2030-02-14
Completion
2030-02-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305482 on ClinicalTrials.gov